Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...

Sen-Jam Pharmaceutical is excited to announce the preliminary results from its recently completed Phase 2 clinical trial evaluating the safety and efficacy of SJP-002C, a novel therapeutic for the ...

("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular ...

The data for Aptevo Therapeutics Inc. (NASDAQ: APVO) herein utilizes proprietary algorithms produced by Stock Traders Daily and refined since the turn of the century.

Is Aptevo Therapeutics Inc. (APVO) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Aptevo Therapeutics Inc. is one of 1011 companies in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mipletamig is under clinical development by Aptevo Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...